Currently, EGFR tyrosine kinase inhibitors (TKIs) are widely used in the treatment of NSCLC patients with EGFR mutations, spanning across various stages, including first‐line treatment for advanced NSCLC and both neoadjuvant and adjuvant therapies for early or locally advanced NSCLC [8, 9, 10]. Here, EGFR is linked to non-small cell lung carcinoma.